US2005064453A1PendingUtilityA1
Diagnostics and therapeutics for early-onset menopause
Priority: Jun 30, 1999Filed: May 3, 2004Published: Mar 24, 2005
Est. expiryJun 30, 2019(expired)· nominal 20-yr term from priority
A61P 43/00A61P 37/00A61P 29/00C12Q 2600/158G01N 33/5008A61P 1/04G01N 33/502C12Q 1/6883G01N 33/5091A61P 17/06C12Q 2600/156C12Q 2600/172C12Q 1/6827
47
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A method of predicting whether a subject is predisposed to developing early-onset menopause is provided. The method involves genotyping a patient at the IL-1 gene loci.
Claims
exact text as granted — not AI-modified1 . A kit for determining a woman's predisposition to early-onset menopause comprising a first primer that hybridizes 5′ or 3′ to a marker of an IL-1-related gene associated with early-onset menopause, wherein said kit is used to detect a predisposition to early-onset menopause.
2 . The kit of claim 1 , wherein said marker is selected from the group consisting of: IL-1RN (+2018); IL-1RN (VNTR); IL-1A (222/223); IL-1A (gz5/gz6); IL-1A (−889); IL-1B (+3954); IL-1B (−511); gaat.p33330; Y31; IL-1RN exon 1ic (1812); IL-1RN exon 1ic (1868); IL-1RN exon 1ic (1887); Pic (1731); IL-1A (+4845); IL-1B (+6912) allele 1; and IL-1B (−31) allele 2.
3 . The kit as of claim 2 , further comprising a second primer that hybridizes 3′ to said marker when said first primer hybridizes 5′ and hybridizes 5′ to said marker when said first primer hybridizes 3′.
4 . The kit of claim 3 , wherein said first primer and said second primer hybridize to a region that includes said marker, wherein said region is in the range of between about 50 and 1000 base pairs.
5 . The kit of claim 3 , wherein said primers are selected from the group consisting of:
(SEQ ID No. 5)
5′ CTC AGC AAC ACT CCT AT 3′;
(SEQ ID No.6)
5′ TCC TGG TCT GCA GGT AA 3′;
(SEQ ID No.7)
5′ CTA TCT GAG GAA CAA CCA ACT AGT AGC 3′;
(SEQ ID No.8)
5′ TAG GAC ATT GCA CCT AGG GTT TGT 3′;
(SEQ ID No.9)
5′ CTC AGG TGT CCT CGA AGA AAT CAA A 3′;
(SEQ ID No.10)
5′ GCT TTT TTG CTG TGA GTC CCG 3′;
(SEQ ID No.11)
5′ AAG CTT GTT CTA CCA CCT GAA CTA GGC 3′;
(SEQ ID No.12)
5′ TTA CAT ATG AGC CTT CCA TG 3′;
(SEQ ID No.13)
5′ TGG CAT TGA TCT GGT TCA TC 3′;
(SEQ ID No.14)
5′ GTT TAG GAA TCT TCC CAC TT 3′;
(SEQ ID No.15)
5′ ATG GTT TTA GAA ATC ATC AAG CCT AGG GCA 3′;
(SEQ ID No.16)
5′ AAT GAA AGG AGG GGA GGA TGA CAG AAA TGT 3′;
(SEQ ID No.17)
5′ TTACGCAGATAAGAACCAGTTTGG 3′;
(SEQ ID No.18)
5′ TTTCCTGGACGCTTGCTCACCAG 3′;
(SEQ ID No.19)
5′ ATGTATAGAATTCCATTCCTG 3′;
(SEQ ID No.20)
5′ TAAAATCAAGTGTTGATGTAG 3′;
(SEQ ID No.21)
5′ GGGATTACAGGCGTGAGCCACCGCG 3′;
(SEQ ID No.22)
5′ TTAGTATTGCTGGTAGTATTCATAT 3′;
(SEQ ID No.23)
5′ GAGGCGTGAGAATCTCAAGA 3′;
(SEQ ID No.24)
5′ GTGTCCTCAAGTGGATCTGG 3′;
(SEQ ID No.25)
5′ GGGCAACAGAGCAATGTTTCT 3′;
and
(SEQ ID No.26)
5′ CAGTGTGTCAGTGTACTGTT 3′.
6 . The kit of claim 2 , further comprising a DNA sampling means.
7 . The kit of claim 2 , further comprising a control.
8 . The kit of claim 2 , further comprising a DNA detection means.
9 . The kit of claim 3 , wherein said first primer and/or said second primer further comprises a detectable label.Join the waitlist — get patent alerts
Track US2005064453A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.